Abstract:
Objective
To observe the clinical effect of pidotimod oral liquid on children with bronchial asthma.
Methods
A total of 120 children with asthma were included as the research subjects, and were randomly divided into two groups: the observation group(60 cases) and the control group(60 cases). The children in both groups were given conventional expectant treatment of oxygen inhalation, relieving cough, eliminating phlegm, and spasmolytic, antiasthmatic and anti-infection therapy; the children in observation group was also treated with pidotimod oral liquid, four weeks as a course for 3 courses. Observe the clinical symptoms, changes in symptoms and lung function, immune function and the clinical effect.
Results
The total effective rate of observation group was 93.3%(56/60) significantly higher than that of control group(73.3%,44/60),the difference being statistical(P<0.05).After treatment，FEV1, FVC and maximal expiratory flow of observation group were significantly higher than those of control group, and there was statistical difference(P<0.05).The level of CD3+ and CD4+ and CD4+/CD8+ ratio were significantly higher in observation group than in control group after treatment, while CD8+ level was significantly lower, the difference being statistical(P<0.05).
Conclusion
Pidotimod oral liquid has significant effect in treating children with bronchial asthma; it is safe and can significantly improve the children's immunity, which is worthy of clinical promotion.

Key words: Asthma, Pidotimod, Immunologic function, Children